Eni SpA vs Zoetis Inc — how do they compare? Eni SpA trades at $48.36 (market cap $70.34B), while Zoetis Inc trades at $76.56 (market cap $31.25B). The key difference: Eni SpA is far larger — about 2.3× Zoetis Inc's market cap, and Eni SpA pays the higher dividend (4.99%). Which is the better fit depends on your goals.
| E | ZTS | |
|---|---|---|
Market Cap | $70.34B | $31.25B |
Sector | Energy | Health |
52-Week High | $57.61 | $156.76 |
52-Week Low | $32.93 | $71.91 |
Enterprise Value | $89.25B | $38.54B |
Dividend Yield | 4.99% | 2.84% |
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $49.55, up 0.22% with a bullish technical signal supported by moving averages. The company shows stable cash flow generation with $238M net cash flow in 2025 and maintains a dividend of $0.63. Recent strategic expansions into renewable fuels, lithium, and energy trading through partnerships with BMW, Mercuria, and UKAEA highlight diversification efforts. Valuation metrics appear reasonable with P/E of 21.6 and EV/EBITDA of 3.83, though revenue has declined from $132.5B in 2022 to $82.15B in 2025.
The outlook balances strategic growth initiatives against revenue pressures. Opportunities exist in energy transition projects and trading expansion, but risks include oil price volatility and execution challenges. Analyst sentiment is mixed with 34.6% buy ratings versus 61.5% hold, suggesting cautious optimism. The stock's investment case hinges on successful diversification while managing core energy market exposure.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →